Salvia BioElectronics is a clinical-stage medical device company pioneering a neuromodulation therapy for people with debilitating migraine. Its MySalvia neuromodulation platform is poised to set a new standard of care and restore quality of life to hundreds of millions of people who suffer with resistant migraine, a condition in which significant disability persists despite multiple treatments.

Jill Schiaparelli’s appointment reflects Salvia’s deliberate expansion of its U.S. leadership team as the company advances its investigational MySalvia Therapy through clinical evaluation and continues to move toward commercialization in the US and the EU.

Bringing nearly three decades of leadership across medical devices, neuromodulation, and commercial strategy, Jill joins Salvia with a proven track record of guiding innovative medical technology companies through the full product lifecycle. Her specialized background in scaling high-growth ventures and establishing robust clinical validation pathways will be instrumental in steering Salvia’s corporate governance and cross-border commercial strategy.

Hubert Martens, Founder and CEO of Salvia, said: “We are delighted to welcome Jill as Board Chair of Salvia BioElectronics. Jill has spent her career building and leading medical device companies through the full commercial journey, from development through FDA clearance and into the market. Her direct experience in the neuromodulation space, combined with her depth of leadership experience, is exactly the profile we need. As we advance MySalvia Therapy through the critical phases of clinical development and toward commercialization, her leadership at the board level will be invaluable.”

He added: “Our collaboration with Coulter Partners was vital to this search. Navigating a transatlantic placement within a highly technical and niche clinical sector requires deep domain expertise. The Coulter Partners team demonstrated impressive international reach and real strategic agility, acting as a seamless extension of our business to secure a world-class U.S. leader who shares our vision to deliver drug-free relief to millions of migraine sufferers.”

Penny Sadler, Managing Partner at Coulter Partners, said: “Identifying a Chair in the niche neuromodulation medical device market in the U.S. is particularly challenging given the complex market dynamics and limited talent pool of leaders who combine venture-backed CEO experience, deep commercial expertise, and a proven ability to scale within a highly specialized and evolving segment. Our goal was to uncover an executive who could translate pioneering science into an impactful U.S. commercial strategy, and Jill’s phenomenal track record of taking breakthrough bioelectronic platforms from inception through to regulatory milestones makes her uniquely positioned to guide Salvia through its next growth inflection point.”

Nona Footz, Client Partner at Coulter Partners, added: “Jill is the unique combination of deep technical experience coupled with high EQ, a leadership track record of making an impact in growing companies, and leveraging her knowledge and network to help drive team performance. Her innate understanding of operational scale-up within the American healthcare ecosystem, paired with her extensive board-level governance experience, ensures that Salvia is remarkably well-positioned. It was a privilege to partner with Hubert and the Salvia Board to complete this high-impact international placement.”

—

Jill Schiaparelli, Chair of the Board of Directors, Salvia BioElectronics

Jill Schiaparelli is a highly accomplished executive with extensive experience driving commercial strategy, corporate development, and regulatory execution within the global healthcare and medical technology sectors. Most recently, she built Avation Medical from the ground up as Co-Founder and CEO, leading the development and commercialization of the first FDA-cleared, closed-loop wearable neuromodulation system for bladder control.

Her extensive operational track record includes serving as Chief Marketing Officer and project director for strategic growth at AxoGen (NASDAQ: AXGN), and Chief Strategy and Business Officer at ApaTech, where she was instrumental in driving commercial expansion prior to its acquisition by Baxter Healthcare. Jill began her healthcare career with an intensive commercial foundation at Johnson & Johnson (Ethicon), following nearly a decade spent working in investment banking.

In addition to her executive history, Jill brings extensive corporate governance expertise to Salvia. She currently serves on the Board of Directors for OssDsign AB and the Global Nerve Foundation, and contributes as a consulting Executive in Residence at the Rockefeller Neuroscience Institute at WVU Medicine. Jill holds an MBA in Finance and Business Management from the Stern School of Business at New York University and a B.S. in Business Administration from the Questrom School of Business at Boston University.

About Salvia BioElectronics

About Coulter Partners